Considerations for Controlling Invasive Meningococcal Disease in High Income Countries

Vaccine. 2012 May 30;30 Suppl 2:B57-62. doi: 10.1016/j.vaccine.2011.12.093.


The development of conjugate vaccines has enabled the prevention and control of Neisseria meningitidis caused by serogroups A, C, W-135 and Y. Vaccines that provide protection against a broad number of serogroup B strains likely will be available soon to enable greater control of meningococcal disease in high income countries. We present an argument for adequate post-marketing surveillance to monitor epidemiological shifts and to provide a context for the safety and reactogenicity of serogroup B vaccines, including the newer recombinant vaccines. We also offer a series of recommendations to address possible concerns about vaccine safety.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Developed Countries
  • Humans
  • Meningitis, Bacterial / epidemiology
  • Meningitis, Bacterial / prevention & control
  • Meningococcal Infections / epidemiology*
  • Meningococcal Infections / prevention & control*
  • Meningococcal Vaccines / administration & dosage*
  • Meningococcal Vaccines / immunology*
  • Neisseria meningitidis / classification
  • Neisseria meningitidis / immunology
  • Neisseria meningitidis / isolation & purification*
  • Product Surveillance, Postmarketing / methods
  • Sentinel Surveillance*
  • Sepsis / epidemiology
  • Sepsis / prevention & control


  • Meningococcal Vaccines